Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMN AMN Healthcare Services	$21.15 -3.5%	$20.76	$17.45 ▼ $70.07	$838.82M	0.19	895,108 shs	472,599 shs
GH Guardant Health	$48.55 -1.2%	$44.52	$20.14 ▼ $52.92	$6.09B	1.38	2.14 million shs	2.39 million shs
IDYA IDEAYA Biosciences	$21.42 -1.2%	$19.65	$13.45 ▼ $44.42	$1.90B	0.05	1.02 million shs	950,501 shs
TMDX TransMedics Group	$127.53 +3.2%	$115.04	$55.00 ▼ $177.37	$4.18B	2.1	1.37 million shs	1.01 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMN AMN Healthcare Services	-3.59%	-3.42%	+1.77%	-11.66%	-60.09%
GH Guardant Health	-1.20%	-1.52%	+27.76%	+4.50%	+64.24%
IDYA IDEAYA Biosciences	-1.15%	-4.33%	+13.82%	+18.93%	-42.09%
TMDX TransMedics Group	+3.21%	-10.16%	+2.64%	+80.15%	-8.28%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMN AMN Healthcare Services	4.2584 of 5 stars	3.1	2.0	4.3	2.4	1.7	1.9
GH Guardant Health	4.2496 of 5 stars	3.5	3.0	4.3	1.9	2.5	0.6
IDYA IDEAYA Biosciences	3.6109 of 5 stars	3.5	2.0	4.4	1.4	1.7	0.0
TMDX TransMedics Group	1.3318 of 5 stars	1.4	2.0	0.0	1.5	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMN AMN Healthcare Services	2.25	Hold	$32.08	51.70% Upside
GH Guardant Health	3.00	Buy	$53.76	10.74% Upside
IDYA IDEAYA Biosciences	2.93	Moderate Buy	$54.27	153.37% Upside
TMDX TransMedics Group	2.80	Moderate Buy	$127.33	-0.15% Downside

Current Analyst Ratings Breakdown

Latest AMN, TMDX, GH, and IDYA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	TMDX TransMedics Group	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$130.00 ➝ $150.00
6/17/2025	TMDX TransMedics Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/13/2025	GH Guardant Health	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$60.00 ➝ $65.00
6/4/2025	TMDX TransMedics Group	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$125.00 ➝ $145.00
6/3/2025	TMDX TransMedics Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/22/2025	IDYA IDEAYA Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$63.00 ➝ $66.00
5/13/2025	AMN AMN Healthcare Services	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$30.00 ➝ $25.50
5/9/2025	TMDX TransMedics Group	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$125.00 ➝ $130.00
5/9/2025	TMDX TransMedics Group	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$105.00 ➝ $125.00
5/6/2025	GH Guardant Health	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$50.00 ➝ $60.00
5/5/2025	GH Guardant Health	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform

(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMN AMN Healthcare Services	$2.98B	0.27	$13.22 per share	1.60	$18.56 per share	1.14
GH Guardant Health	$739.02M	8.14	N/A	N/A	($1.13) per share	-42.96
IDYA IDEAYA Biosciences	$7M	267.99	N/A	N/A	$12.25 per share	1.75
TMDX TransMedics Group	$488.23M	8.84	$1.70 per share	75.09	$6.81 per share	18.73

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMN AMN Healthcare Services	-$146.98M	-$4.33	N/A	8.74	N/A	-5.80%	13.39%	4.17%	8/6/2025 (Estimated)
GH Guardant Health	-$436.37M	-$3.39	N/A	N/A	N/A	-53.82%	-1,200.44%	-26.77%	8/6/2025 (Estimated)
IDYA IDEAYA Biosciences	-$274.48M	-$3.59	N/A	N/A	N/A	N/A	-29.28%	-27.68%	8/5/2025 (Estimated)
TMDX TransMedics Group	$35.46M	$1.36	93.77	89.18	N/A	10.03%	21.88%	6.15%	7/30/2025 (Estimated)

Latest AMN, TMDX, GH, and IDYA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	AMN AMN Healthcare Services	$0.19	$0.45	+$0.26	-$0.03	$670.08 million	$689.53 million
5/8/2025	Q1 2025	TMDX TransMedics Group	$0.29	$0.70	+$0.41	$0.70	$123.39 million	$143.54 million
5/6/2025	Q1 2025	IDYA IDEAYA Biosciences	-$0.75	-$0.82	-$0.07	-$0.82	$2.10 million	N/A
4/30/2025	Q1 2025	GH Guardant Health	-$0.57	-$0.49	+$0.08	-$0.77	$189.91 million	$203.47 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMN AMN Healthcare Services	N/A	N/A	N/A	N/A	N/A
GH Guardant Health	N/A	N/A	N/A	N/A	N/A
IDYA IDEAYA Biosciences	N/A	N/A	N/A	N/A	N/A
TMDX TransMedics Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMN AMN Healthcare Services	1.39	1.08	1.08
GH Guardant Health	N/A	4.11	3.76
IDYA IDEAYA Biosciences	N/A	13.92	13.92
TMDX TransMedics Group	1.92	9.10	8.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMN AMN Healthcare Services	99.23%
GH Guardant Health	92.60%
IDYA IDEAYA Biosciences	98.29%
TMDX TransMedics Group	99.67%

Insider Ownership

Company	Insider Ownership
AMN AMN Healthcare Services	0.93%
GH Guardant Health	6.10%
IDYA IDEAYA Biosciences	2.50%
TMDX TransMedics Group	7.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMN AMN Healthcare Services	2,968	38.28 million	37.93 million	Optionable
GH Guardant Health	2,021	123.89 million	116.33 million	Not Optionable
IDYA IDEAYA Biosciences	80	87.58 million	85.39 million	Optionable
TMDX TransMedics Group	210	33.82 million	31.46 million	Optionable

AMN, TMDX, GH, and IDYA Headlines

Recent News About These Companies

TransMedics Group, Inc. (NASDAQ:TMDX) Shares Purchased by Cornerstone Wealth Management LLC

June 21 at 4:05 AM | marketbeat.com

Brokerages Set TransMedics Group, Inc. (NASDAQ:TMDX) PT at $125.11

June 20, 2025 | americanbankingnews.com

TransMedics Group, Inc. (NASDAQ:TMDX) Shares Bought by SG Americas Securities LLC

June 19, 2025 | marketbeat.com

TransMedics Group (NASDAQ:TMDX) Price Target Raised to $150.00 at Oppenheimer

June 19, 2025 | americanbankingnews.com

Boasting A 18% Return On Equity, Is TransMedics Group, Inc. (NASDAQ:TMDX) A Top Quality Stock?

June 18, 2025 | finance.yahoo.com

TransMedics Group (NASDAQ:TMDX) Stock Price Down 4.9% - Should You Sell?

June 18, 2025 | marketbeat.com

TransMedics Group (NASDAQ:TMDX) Price Target Raised to $150.00

June 17, 2025 | marketbeat.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating TransMedics Group, Inc. (TMDX) And Encourages Shareholders to Connect

June 17, 2025 | accessnewswire.com

TransMedics Group's (TMDX) Hold Rating Reiterated at Needham & Company LLC

June 17, 2025 | marketbeat.com

TransMedics Group, Inc. (NASDAQ:TMDX) Receives Average Recommendation of "Moderate Buy" from Analysts

June 17, 2025 | marketbeat.com

Handelsbanken Fonder AB Sells 72,000 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

June 16, 2025 | marketbeat.com

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against TransMedics Group, Inc. (TMDX) And Encourages Shareholders to Reach Out

June 15, 2025 | accessnewswire.com

Price Over Earnings Overview: TransMedics Group

June 13, 2025 | benzinga.com

These 24 Stocks Are Ripe for a Short Squeeze

June 12, 2025 | schaeffersresearch.com

Bronstein, Gewirtz & Grossman, LLC Encourages TransMedics Group, Inc. (TMDX) Stockholders to Inquire about Securities Investigation

June 12, 2025 | accessnewswire.com

Mid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in May

June 12, 2025 | marketbeat.com

TransMedics Group, Inc. (NASDAQ:TMDX) Insider Sells $95,902.80 in Stock

June 11, 2025 | insidertrades.com

Insider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) Insider Sells 686 Shares of Stock

June 10, 2025 | marketbeat.com

Kuehn Law Encourages Investors of TransMedics Group, Inc. to Contact Law Firm

June 10, 2025 | globenewswire.com

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against TransMedics Group, Inc. (TMDX) and Encourages Investors to Learn More About the Investigation

June 10, 2025 | accessnewswire.com

TransMedics Group, Inc. (TMDX): A Bull Case Theory

June 9, 2025 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Intel’s Turnaround May Be the Best Bet No One’s Watching
By Jeffrey Neal Johnson | May 30, 2025
View Intel’s Turnaround May Be the Best Bet No One’s Watching
Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Among the Market’s Most Shorted: 2 Firms With +40% Short Interest
By Leo Miller | June 3, 2025
View Among the Market’s Most Shorted: 2 Firms With +40% Short Interest
Why Super Micro Computer's Upside Could Trigger a Short Squeeze
By Gabriel Osorio-Mazilli | June 3, 2025
View Why Super Micro Computer's Upside Could Trigger a Short Squeeze
3 Penny Stocks Analysts Believe Are Headed Higher
By Chris Markoch | June 4, 2025
View 3 Penny Stocks Analysts Believe Are Headed Higher

AMN, TMDX, GH, and IDYA Company Descriptions

AMN Healthcare Services NYSE:AMN

$21.15 -0.76 (-3.47%)

Closing price 06/23/2025 03:59 PM Eastern

Extended Trading

$20.96 -0.19 (-0.92%)

As of 06/23/2025 04:27 PM Eastern

AMN Healthcare Services, Inc. provides healthcare workforce solutions and staffing services to healthcare facilities in the United States. It operates through three segments: Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions. The Nurse and Allied Solutions segment offers travel nurse staffing, labor disruption staffing, local staffing, international nurse and allied permanent placement, and allied staffing solutions. The Physician and Leadership Solutions segment provides locum tenens staffing, healthcare interim leadership staffing, executive search, and physician permanent placement solutions. The Technology and Workforce Solutions segment offers language services, vendor management systems, workforce optimization, and outsourced solutions. The company also provides allied health professionals, such as physical therapists, respiratory therapists, occupational therapists, medical and radiology technologists, lab technicians, speech pathologists, rehabilitation assistants, and pharmacists. It offers its services under the brands, including AMN Healthcare, Nursefinders, HealthSource Global Staffing, O'Grady Peyton International, Connetics, Medical Search International, DRW Healthcare Staffing, and B.E. Smith. AMN Healthcare Services, Inc. was founded in 1985 and is headquartered in Dallas, Texas.

Guardant Health NASDAQ:GH

$48.55 -0.59 (-1.20%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$49.06 +0.51 (+1.04%)

As of 06/23/2025 07:57 PM Eastern

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

IDEAYA Biosciences NASDAQ:IDYA

$21.42 -0.25 (-1.15%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$21.42 -0.01 (-0.02%)

As of 06/23/2025 04:52 PM Eastern

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

TransMedics Group NASDAQ:TMDX

$127.53 +3.97 (+3.21%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$127.78 +0.25 (+0.19%)

As of 06/23/2025 07:59 PM Eastern

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time